Lupin announced today that its subsidiary Lupin Pharmaceuticals has received final approval for its Irbesartan Tablets, 75 mg, 150 mg and 300 mg from the United States Food and Drugs Administration (US FDA) to market a generic version of Sanofi Aventis US, LLC’s (Sanofi Aventis) Avapro Tablets, 75 mg, 150 mg and 300 mg strengths.
Lupin’s Irbesartan Tablets, 75 mg, 150 mg and 300 mg are the AB-rated generic equivalent of Sanofi Aventis’s Avapro tablets. Irbesartan is an angiotensin II receptor antagonist and is indicated for the treatment of hypertension and nephropathy in type II diabetic patients.
EP News Bureau
- Advertisement -
